Collaboration Will Target New Tools to Enhance Early Cancer Detection and Intervention AUSTIN, Texas & FRANKLIN LAKES, N.J.–Luminex Corporation (NASDAQ: LMNX), a worldwide leader in multiplexed solutions, and global medical technology company BD (NYSE: BDX), through its BD Diagnostics-TriPath platform, today announced the signing of a development and supply agreement. Under the terms of the […]
Osmetech plc (‘Osmetech’) (LSE:OMH), the international molecular diagnostics business, today announced that it has signed an agreement with QIAGEN (Nasdaq: QGEN; Frankfurt Prime Standard: QIA) pursuant to which Osmetech will adapt a QIAplex-based respiratory viral test for use on Osmetech’s recently launched eSensor XT-8 molecular diagnostics system. Under the terms of the agreement, QIAGEN will […]
SUNNYVALE, Calif., Sept. 29 — Cepheid (Nasdaq: CPHD) today announced it has received clearance from the U.S. Food & Drug Administration (FDA) to market its Xpert(TM) MRSA/SA Skin and Soft Tissue Infection (SSTI) test, which runs on the GeneXpert(R) System, for the rapid detection of Methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus aureus (SA, typically Methicillin-sensitive) […]
Clarient, Inc. (Nasdaq:CLRT) and Definiens, Inc. jointly announced today that they established a strategic partnership to employ a series of image analysis platforms for Clarient’s in-house research and development, and Web-based customer portal PATHSiTE(SM). Under a five year collaborative agreement, Clarient and Definiens plan to develop and commercialize tools that will help to evaluate quantitative […]
Sequenom, Inc. (NASDAQ:SQNM), a leading provider of genetic-analysis and molecular diagnostic solutions, announced additional, positive results from screening studies using the Company’s noninvasive circulating cell-free fetal (ccff) nucleic acid SEQureDx(TM) Technology, which enables the detection of fetal aneuploidy, including Down syndrome from maternal blood, at its Analyst Briefing in New York City. Among the data […]
WOBURN, Mass., Sept. 23 — U.S. Genomics today announced it has received a $4.5 million equity investment from BD (Becton, Dickinson and Company) and that the companies have entered into a strategic collaboration for development of a novel infectious disease diagnostic platform. The collaboration will focus on application of U.S. Genomics’ DirectLinear Analysis(TM) technology (DLA) […]
Acquisition of Center for Molecular Medicine Positions Sequenom for Commercial Launch of SEQureDx(TM) Test in First Half 2009 Daniel H. Farkas, Ph.D. to Join Sequenom Management Team SAN DIEGO–Sequenom (NASDAQ:SQNM – News) today announced that it entered into an agreement to acquire the Center for Molecular Medicine (CMM), a Clinical Laboratory Improvement Act (CLIA) certified […]
PHILADELPHIA — Researchers have demonstrated a new instrument that makes it possible to detect and quantify multiple different clinically important proteins in a single tumor sample using conventional staining. Currently, pathologists usually need a separate tissue slice for each protein they want to examine, making it impossible to see how molecules interact within individual cells. […]
e2v biosensors, a subsidiary of e2v technologies plc, and AbD Serotec, the division for research and diagnostic antibodies of MorphoSys AG, today launched a research programme to establish e2v’s proprietary biosensor system Visucare™, a novel detection technology for biomarkers using a single-antibody immunoassay. The Visucare™ system will be used for protein quantification in point of […]
Sequenom, Inc. (Nasdaq: SQNM) today announced that it has secured exclusive rights to fundamental patent rights for digital PCR technologies and methods through a licensing agreement with Genomic Nanosystems, LLC, a wholly owned subsidiary of the Cytonix Corporation. The exclusively licensed rights include United States Patent Nos. 6,143,496 and 6,391,559 and pending applications. The license […]
Pay Invoice
Latest Blogs
-
New Report Details Higher Education Science R&D Spending
February 27, 2026 3:23 pm
-
Single Use Leads Bioreactor Market Growth
December 30, 2025 6:04 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
